Oxygenta Pharmaceutical Ltd — Important, 22-10-2025: Company Update

Oxygenta Pharmaceutical Limited's manufacturing license for products including Etoricoxib, Vildagliptin, Lacosamide, and Telmisartan has been suspended for seven days by the Drugs Control Administration, Government of Telangana. This action stems from violations of certain rules under the Drugs and Cosmetics Act. The suspension is anticipated to impact the company's operations and finances, projecting a potential revenue loss of Rs. 0.20 Cr for the duration. This temporary halt affects key product lines, influencing the company's short-term production and earnings.